CytomX Therapeutics, Inc.
Moat Score — CytomX Therapeutics, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Proprietary PROBODY masking technology and associated patent estate represent genuine, differentiated intellectual property validated by multiple blue-chip pharma partnerships. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage biotech with no products, CytomX has no manufacturing or cost-scale advantage; it relies on partner funding to offset R&D burn. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No commercial products exist yet, so pricing power cannot be assessed; future pricing will depend on eventual approval and payer negotiations. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effect applies to a clinical-stage drug development business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Pharma partners who have invested years integrating PROBODY technology into their own pipelines face switching costs, but recent partnership terminations show this stickiness is limited. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The oncology ADC and masking-technology space includes multiple well-funded competitors (Bicycle Therapeutics, Werewolf Therapeutics, big pharma), offering no efficient-scale barrier to CytomX specifically. |